NO20053972L - Aminosyre-avledede prodrug av propofol, sammensetninger og anvendelse derav. - Google Patents

Aminosyre-avledede prodrug av propofol, sammensetninger og anvendelse derav.

Info

Publication number
NO20053972L
NO20053972L NO20053972A NO20053972A NO20053972L NO 20053972 L NO20053972 L NO 20053972L NO 20053972 A NO20053972 A NO 20053972A NO 20053972 A NO20053972 A NO 20053972A NO 20053972 L NO20053972 L NO 20053972L
Authority
NO
Norway
Prior art keywords
propofol
compositions
amino acid
acid derived
prodmg
Prior art date
Application number
NO20053972A
Other languages
English (en)
Inventor
Mark A Gallop
Kenneth C Cundy
Feng Xu
Vivek Sasikumar
Thomas W Woiwode
Original Assignee
Xenoport Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenoport Inc filed Critical Xenoport Inc
Publication of NO20053972L publication Critical patent/NO20053972L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/24—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/14—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated
    • C07C225/16—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C329/00—Thiocarbonic acids; Halides, esters or anhydrides thereof
    • C07C329/02—Monothiocarbonic acids; Derivatives thereof
    • C07C329/04—Esters of monothiocarbonic acids
    • C07C329/06—Esters of monothiocarbonic acids having sulfur atoms of thiocarbonic groups bound to acyclic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer propofol prodmg, fremgangsmåte for fremstilling av propofol prodmg, farmasøytiske sammensetninger av propofol prodmg og fremgangsmåter for anvendelse av propofol prodmg og farmasøytiske sammensetninger derav for å behandle eller hindre sykdommer eller forstyrrelser slike som migrene hodepine og post-kjemoterapi eller postoperativ kimrgikvalme og oppkast.
NO20053972A 2003-01-28 2005-08-25 Aminosyre-avledede prodrug av propofol, sammensetninger og anvendelse derav. NO20053972L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44331503P 2003-01-28 2003-01-28
PCT/US2004/002537 WO2005021024A1 (en) 2003-01-28 2004-01-28 Amino acid derived prodrugs of propofol, compositions and uses thereof

Publications (1)

Publication Number Publication Date
NO20053972L true NO20053972L (no) 2005-08-25

Family

ID=34272366

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053972A NO20053972L (no) 2003-01-28 2005-08-25 Aminosyre-avledede prodrug av propofol, sammensetninger og anvendelse derav.

Country Status (11)

Country Link
US (1) US7220875B2 (no)
EP (1) EP1587527A4 (no)
JP (1) JP2007521250A (no)
KR (1) KR20060055438A (no)
CN (2) CN1744908A (no)
CA (1) CA2510677A1 (no)
MX (1) MXPA05007792A (no)
NO (1) NO20053972L (no)
NZ (1) NZ540699A (no)
WO (1) WO2005021024A1 (no)
ZA (1) ZA200504940B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005044201A2 (en) * 2003-10-24 2005-05-19 Auspex Pharmaceuticals, Inc. Ph sensitive prodrugs of 2,6-diisopropylphenol
WO2006017351A1 (en) * 2004-07-12 2006-02-16 Xenoport, Inc. Prodrugs of propofol, compositions and uses thereof
PT1781596E (pt) * 2004-07-12 2009-01-12 Xenoport Inc Pró-fármacos de propofol derivados de aminoácidos, composições e utilizações dos mesmos
JP2008525501A (ja) * 2004-12-23 2008-07-17 ゼノポート，インコーポレイティド セリンアミノ酸誘導のプロポフォールのプロドラッグ、その使用及び結晶体
US20080161400A1 (en) * 2006-10-26 2008-07-03 Xenoport, Inc. Use of forms of propofol for treating diseases associated with oxidative stress
CA2685813A1 (en) 2007-05-09 2008-11-20 Pharmacofore, Inc. Therapeutic compounds
EP2810927A1 (en) 2007-05-09 2014-12-10 Sowood Healthcare LLC Therapeutic compounds
US20090005444A1 (en) * 2007-06-21 2009-01-01 Xenoport, Inc. Use of propofol prodrugs for treating alcohol withdrawal, central pain, anxiety or pruritus
US20090076141A1 (en) * 2007-09-14 2009-03-19 Xenoport, Inc. Use of Propofol Prodrugs for Treating Neuropathic Pain
WO2009092071A2 (en) * 2008-01-18 2009-07-23 Shire Llc Amino acid and peptide pro-drugs of phenolic analgesics and uses thereof
CN101298426B (zh) * 2008-06-17 2012-08-22 靳广毅 2,6-二异丙基苯酚的水溶性衍生物及其应用
KR20110134510A (ko) * 2009-04-02 2011-12-14 샤이어 엘엘씨 오피오이드의 신규한 디카르복실산 연결 아미노산 및 펩티드 프로드러그와 그 용도
WO2011050095A2 (en) * 2009-10-20 2011-04-28 The General Hospital Corporation Prevention and treatment of post-operative cognitive dysfunction (pocd)
CN101906039B (zh) * 2010-06-23 2013-05-08 四川大学华西医院 取代苯酚的羟基酸酯化合物、制备方法及在药物中的应用
FR2976944A1 (fr) * 2011-06-21 2012-12-28 Centre Nat Rech Scient Prodrogues peptidiques
CN102381972B (zh) * 2011-09-08 2013-10-30 四川大学华西医院 带有酯结构末端的丙泊酚羟基酸酯类化合物及其制备方法和应用
CN102617380B (zh) * 2012-03-12 2014-04-02 成都一平医药科技发展有限公司 氨基酸与丙泊酚的碳酸二酯水溶性衍生物及其用途
CN103880754A (zh) * 2012-12-21 2014-06-25 西藏海思科药业集团股份有限公司 一种丙泊酚碱性氨基酸酯盐
US9643917B2 (en) 2014-02-17 2017-05-09 Jiangsu Nhwaluokang Pharmceutical Research And Development Co., Ltd Water-soluble propofol derivatives and uses thereof
CN108558685B (zh) * 2017-06-08 2020-11-20 西安力邦制药有限公司 2,6-二取代苯酚葡甲胺类衍生物及应用
US11547714B2 (en) 2020-02-05 2023-01-10 Epalex Corporation Fospropofol salts, methods and compositions
US11628178B2 (en) 2019-03-26 2023-04-18 Epalex Corporation Fospropofol methods and compositions
US11478490B1 (en) 2021-03-30 2022-10-25 Epalex Corporation Fospropofol formulations
US11439653B1 (en) 2021-03-30 2022-09-13 Epalex Corporation Fospropofol formulations
CN112694414B (zh) 2019-10-22 2023-02-28 四川大学华西医院 一类取代苯酚羟基酸酯含n衍生物、制备和用途
CN111920789A (zh) * 2020-08-17 2020-11-13 中山大学附属第一医院 异丙酚通过促进发育脑多巴胺神经网络形成提高小鼠认知功能的用途
CN116472264A (zh) * 2020-12-21 2023-07-21 加拿大力邦制药有限公司 一种药物偶联物、及其制备方法和用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
ZA791659B (en) 1978-04-17 1980-04-30 Ici Ltd Process and apparatus for spraying liquid
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US4962882A (en) * 1989-11-27 1990-10-16 Sarazen Jr Paul M Ventilator
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
GB9225098D0 (en) 1992-12-01 1993-01-20 Coffee Ronald A Charged droplet spray mixer
GB9226717D0 (en) 1992-12-22 1993-02-17 Coffee Ronald A Induction-operated electro-hydrodynamic spray device with means of modifying droplet trajectories
GB9406171D0 (en) 1994-03-29 1994-05-18 Electrosols Ltd Dispensing device
GB9406255D0 (en) 1994-03-29 1994-05-18 Electrosols Ltd Dispensing device
GB9410658D0 (en) 1994-05-27 1994-07-13 Electrosols Ltd Dispensing device
DE69621604T2 (de) 1995-03-14 2002-11-28 Siemens Ag Ultraschall-zerstäuber mit abnehmbarer präzisionsdosiereinheit
AU690438B2 (en) 1995-03-14 1998-04-23 Siemens Aktiengesellschaft Ultrasonic atomizer device with removable precision dosating unit
US5954047A (en) 1997-10-17 1999-09-21 Systemic Pulmonary Development, Ltd. Methods and apparatus for delivering aerosolized medication
US6254853B1 (en) * 1998-05-08 2001-07-03 Vyrex Corporation Water soluble pro-drugs of propofol
US6204257B1 (en) * 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
ATE267586T1 (de) * 1999-02-18 2004-06-15 Supergen Inc An phosphocholin gebundene prodrug-derivate
AU3898700A (en) 1999-03-15 2000-10-04 John Claude Krusz Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages
US6362234B1 (en) * 2000-08-15 2002-03-26 Vyrex Corporation Water-soluble prodrugs of propofol for treatment of migrane

Also Published As

Publication number Publication date
US7220875B2 (en) 2007-05-22
CN101255123A (zh) 2008-09-03
MXPA05007792A (es) 2006-01-31
CN1744908A (zh) 2006-03-08
KR20060055438A (ko) 2006-05-23
EP1587527A1 (en) 2005-10-26
JP2007521250A (ja) 2007-08-02
WO2005021024A1 (en) 2005-03-10
AU2004268492B2 (en) 2008-07-31
AU2004268492A1 (en) 2005-03-10
ZA200504940B (en) 2006-09-27
NZ540699A (en) 2007-06-29
CA2510677A1 (en) 2005-03-10
EP1587527A4 (en) 2009-10-21
US20050004381A1 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
SE0301010D0 (sv) Novel compounds
NO20052595L (no) Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser.
SE0301009D0 (sv) Novel compounds
NO20082508L (no) Aminopyrimidiner anvendelige som kinaseinhibitorer
NO20073628L (no) Pyridoner som er nyttige som inhibitorer av kinaser
NO20071915L (no) Diaminotriazolforbindelser nyttige som proteinkinaseinhibitorer
NO20085373L (no) P38 inhibitorer, deres fremstilling og anvendelse
BRPI0410117A (pt) composto, composição farmacêutica, método para o tratamento de uma doença ou condição mediada por jak3, e, processo para a preparação de um composto
TW200519075A (en) Novel compounds
SE0101675D0 (sv) Novel composition
NO20053470L (no) Triazolopyridaziner som proteinkinase-inhibitorer
NO20050122L (no) Prodrug av eksitasjonsaminosyrer
TW200612892A (en) Novel compounds
BR0313176A (pt) Composições de pirazol úteis como inibidores de gsk-3
NO20083918L (no) Dihydridiazepiner anvendelige som inhibitorer av proteinkinaser
MY129328A (en) Triamide-substituted heterobicyclic compounds
WO2005046603A3 (en) Pyridine compounds
NO20072352L (no) Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet
NO20084747L (no) Tetrahydropteridiner anvendbare som inhibitorer av protein kinaser
PT1730146E (pt) Azaindoles úteis como inibidores de jak e outras proteínas quinases
SE0200920D0 (sv) Novel compounds
NO20071619L (no) Fremgangsmate for fremstilling av indazol forbindelse
MXPA05007792A (es) Prodrogas de propofol derivadas de aminoacido, composiciones y usos de las mismas.
TW200630336A (en) Novel compounds
TW200621690A (en) Novel compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application